A diagnosis of Early Breast Cancer (EBC) is the beginning of a journey that extends far beyond the clinic walls. While survival rates are rising, the ripple effects of emotional, physical, and financial continue to reshape lives across Australia and New Zealand.
Our latest Novartis report, Beyond the diagnosis, explores the staggering “hidden” burden of EBC, from the AU$3.26 billion loss in GDP due to productivity shifts, to the 84% of survivors living in the shadow of fear regarding recurrence.
“It is recommended that patients start treatment as early as possible. This improves the chances of survival and overall response rates while limiting the risk of metastatic disease.”
Assoc. Prof. Louise Nott, Medical Oncologist
Investing in early detection and effective treatment of EBC is not only a health or clinical imperative, it is an economic one. Evidence shows that early diagnosis and timely, effective interventions can dramatically reduce healthcare costs by minimising the need for aggressive treatments associated with late-stage disease.
“ Quantifying costs in a clinical setting, whilst challenging, is often the easiest part of a patient’s financial journey. The real expenses outside of immediate healthcare can vary widely, including transportation, parking, wigs, or even port placement. These tend to be the most unforeseen costs.”
Dr Jemma Gilchrist, Clinical Psychologist
Download the Full Report here
